Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in
treating patients with metastatic pancreatic cancer.